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Abstract:   For many years, the “one target, one drug” paradigm has been the driving force behind developments in 
pharmaceutical research. With the recent advances in molecular biology and genomics technologies, the focus is shifting 
toward “drug-holistic” systems based approaches (i.e. systems pharmacology). The integration of large and diverse 
amount of data from chemistry and biology coupled with the development and the application of network-based approaches to cope with 
these data is the next paradigm of drug discovery. Systems pharmacology offers a novel way of approaching drug discovery by developing 
models that consider the global physiological environment of protein targets and their modification by drugs. Studying drug action across 
multiple scales of complexity from molecular and cellular to tissue and organism levels may help identify new druggable disease genes and to 
design new drugs with a better efficacy and clinical safety. 
 
The abstract should not exceed 250 words for review papers summarizing the essential features of the article. 
Keywords: Systems Pharmacology, biological network, drug, protein-protein interactions, pathways, gene expression, 
pharmacogenomics, toxicity. 
1. INTRODUCTION 
 Although the number of new drug candidates reaching 
the market has been stable since 2010 (with 40 new 
molecular entities appearing each year), the attrition rate 
remains high in late stage clinical development phases (II 
and III) leading to a key challenge in drug discovery [1]. The 
main reasons for this attrition in drug development are 
essentially due to a lack of efficacy and the clinical safety 
(toxicology) [2]. Furthermore, the conventional assumption 
that selective ligands act on a single target has slowed down 
the new drug discovery and development process in the 
past years, especially for complex diseases like cancers, 
neurological disorders and diabetes [3-5].  
Recent advances in chemical biology and systems biology 
have shown that most drugs interact with multiple targets 
and although activities against several targets might be 
beneficial, the drawback is that it can also lead to dramatic 
toxicity effects [6,7]. Within the age of big data and with the 
advances in genomic technologies, Next-Generation 
Sequencing (NGS) and Genome-Wide Association Studies 
(GWAS), together with the improvements in mass 
spectroscopy, large amounts of data on genome-wide gene 
expression profiles, proteins and their interactions with 
other biomolecules are being provided [8]. Therefore, the 
mechanisms of action and the safety of drugs can be 
explored not only at the molecular level but also at the level 
of the whole biological system, i.e. systems pharmacology.  
Systems pharmacology considers drug actions and side 
effects in a regulatory network context, drug target and 
disease gene product related, that is understanding the 
mechanism underlying the multiple actions of drugs. In fact, 
multi-target drugs exponentially increase the number of 
pharmacologically relevant target molecules. Low-affinity 
binding of multi-target drugs eases the restrictions of 
druggability, and increases the size of the drugable 
proteome [9-12].  
For example, Imatinib, a drug used in the treatment of 
chronic myelogenous leukemia (CML) is reported to block 
the activity of several nonspecific tyrosine kinases [13].  
Rosiglitazone, which has been used for the treatment of 
type II diabetes mellitus, not only stimulates the peroxisome 
proliferator-activated receptor gamma, but also blocks 
interferon gamma-induced chemokine expression in Graves’ 
disease or ophthalmopathy [14-15]. 
 
Computational approaches and network biology are 
essential components of systems pharmacology, which in 
turn can generate testable hypotheses from large and 
diverse amounts of data. Network biology helps to identify 
the biological mechanism associated with a disease or a 
treatment at several layers of complexity (from molecular 
and cellular to tissue, organs and systems) based on the 
concept that the functions of molecular components in a 
human cell are closely connected and thus a disease is not 
only a consequence of genetic variation but also a result of 
perturbations of intracellular and extracellular networks 
linking tissue and organ systems [16]. Targeting a small 
number of nodes by partial inhibition may be more efficient 
than the total inhibition of a single node. So, network 
biology analysis predictions, point to the capacity to perturb 
robust phenotypes by modulating multiple proteins, instead 
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of deleting individual nodes (gene or protein) within disease 
networks.   
Systems pharmacology is also applied to assess the toxicity 
of a compound (i.e. systems toxicology). In systems 
toxicology, molecular changes in the context of an exposure 
are measured quantitatively, thereby deciphering the casual 
chain of molecular events across different levels of 
organization that link exposure to adverse outcomes. 
Interestingly, such an approach has been gaining attention 
over the past few years through a program launched by the 
OECD in 2012 for the development of Adverse Outcome 
Pathways (AOP) [17]. With the opportunity to integrate and 
to combine all this information in systems pharmacology-
based drug safety predictions, it is expected that some of 
the current challenges in drug discovery can be tackled. 
Here, we will review the status of systems pharmacology 
and showcase data currently exploited in different studies 
as well as the network analysis considered to decipher the 
mechanisms of drug action. All the data sources cited are 
accessible through the hyperlinks in listed table 1. 
 
2. Towards systems level data integration 
 
2.1 Drug-Target 
The role of small molecules in biological systems can only be 
understood in relation to their targets’ functions that can be 
defined as molecular events. Therefore data and knowledge 
on the interaction between proteins and small molecules 
are necessary in order to understand molecular and cellular 
functions [18]. However, chemical-protein interaction 
information is widely spread across various data sources. 
Over many years, the interaction of chemicals with their 
targets have been studied in both biochemistry and 
pharmacology, but much of the existing data is dispersed in 
the vast amounts of literature, locked up in commercial 
databases or sequestered in private datasets. This 
information is now compiled, regularly updated and 
available in large databases such as PubChem [19], ChEMBL 
[20], ChemProt [21], DrugBank [22] or OpenPHACTS [23] 
giving a better overview of the available knowledge that 
drives system level approaches. Based on this data, in silico 
chemogenomic methods have been developed for 
predicting the polypharmacological profiles of bioactive 
compounds and for the identification of potential new 
targets (target fishing approach) [24-25].  
 
Another crucial step in target assessment is the 
quantification of the likelihood of discovering a therapeutic 
molecule that is at the same time safe, and efficacious. For 
this reason it is important to gather information of this kind 
in databases bbased on the toxicity of the compounds, 
together with the interaction of the small molecules with 
the possible targets of a relevant disease-pathway.  
Various research programs in U.S.A., Europe and Japan have 
been for several years focusing their efforts on high-
throughput screening technologies to address the current 
lack of toxicity evaluation of thousands of chemicals, in 
order to improving drug-target information. The U.S. 
Environmental Protection Agency (EPA) ToxCast research 
program and Tox21, involve coordinated effort of 
governmental regulatory and research entities to use high-
throughput bioassays aiming to characterize key elements 
of toxicity pathways, and key biological events that may 
suppose potential targets for chemicals whose interactions 
may lead to disease [26]. Its goal is to acquire enough 
information on a range of chemicals to evaluate their 
bioactivity profiles and predict possible patterns of toxic 
effects and phenotypes that correlate with observed in vivo 
toxicity [27-28]. 
From the European side, SEURAT-1 (Safety Evaluation 
Ultimately Replacing Animal Testing-1) is a research 
program whose underlying assumption is the possibility to 
identify mechanisms of action (MOAs) that are relevant to 
human toxicity, based on existing knowledge such as 
adverse drug reactions (ADRs) of marketed drugs. The 
SEURAT-1 project’s goal was to establish in vitro assays to 
characterize and represent these MOAs. The experimental 
results supporting SEURAT-1 are stored in a web-accessible 
shared repository called the ToxBank Data Warehouse [29]. 
Recently, an H2020-supported collaborative project called 
EU-ToxRisk has been established to translate molecular 
mechanistic understanding of toxicity into safety testing 
strategies (http://www.eu-toxrisk.eu/). 
 
2.2 Chemogenomics and Toxicogenomics 
Chemogenomics and Toxicogenomics have suffered from a 
lack of large publicly available standardized datasets. This 
problem has been addressed in the past years by the 
release of two highly important datasets: the TGP (TG-
GATEs) [30] dataset and DrugMatrix [31]. The first is a 
toxicogenomics database that stores gene expression 
profiles together with traditional toxicological data obtained 
from in vivo (rat) and in vitro (primary rat hepatocytes, 
primary human hepatocytes) exposure to different 
compounds at multiple doses and time points. DrugMatrix 
covers drug-dose-time-tissue combination profiles for 
approximately 600 different compounds administered to 
rats. They demonstrate that the use of both traditional 
toxicity measurements together with gene expression 
analysis enriches the understanding of individual compound 
effects.  
While several toxicogenomics projects made their data 
available via public databases, such as ArrayExpress [32], 
Gene Expression Omnibus (GEO) [33] and Expression Atlas 
[34], data from other projects are more difficult to access. 
Moreover, different experimental designs make it difficult 
to compare and to analyze the results. diXa [35] is a 
warehouse that aims to overcome these drawbacks by 
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defining standard workflows for data preprocessing and 
standard formats for metadata annotation. Besides, diXa 
integrates information from toxicology, chemistry and 
human disease databases along with the original data, 
enhancing and easing the interpretation of data analysis 
results.  
Recently, the National Institutes of Health (NIH) provided a 
Library of Integrated Network-based Cellular Signatures 
(LINCS) containing gene expression profiles for more than 
11,000 compounds measured on several cell lines [36]. Such 
data reporting how a drug induces changes in gene 
expression in different cell-lines coupled with network 
biology and phenotypes can lead to a better understanding 
of drug action and toxicities. 
 
2.3 Protein-Protein Interactions & Drug-Pathways 
One major challenge in the post-genomic era is integration 
of experimental and computational data into specific 
biological pathways, to achieve the understanding of higher-
level complexities of molecular mechanisms in cellular 
processes including the final phenotype. Towards this end 
some databases have been developed that contain wired 
gene-gene and protein-protein information in interaction 
pathways. How is a protein or a gene that has been related 
to an experimental stress or cell disturbance connected to a 
physiological mechanism and a disease phenotype? 
Pathway databases help make this connection by enabling 
the connection between drugs, genes and proteins in a 
model. KEGG (Kyoto Encyclopedia of Genes and Genomes) 
contains protein networks stored as a collection of pathway 
maps that represent wired diagrams of proteins and other 
biomolecules responsible for the cellular functions [37]. 
Other databases contain annotated interactions in the form 
of pathways from the curation of peer-reviewed journals, 
such as Reactome [38], WikiPathways [39] or PID (The 
Pathway Interaction Database [40]. Furthermore, since 
proteins infrequently operate in isolation but rather 
function in highly interconnected cellular pathways, 
integration of protein-protein interactions (PPI), derived 
essentially from high-throughput approaches, including 
yeast two-hybrid screens, immunoprecipitation studies 
followed by mass spectrometry analysis or small scale 
experiments have become a valuable resource of 
information to implemented in network biology and 
systems pharmacology. Databases such as HPRD [41], Intact 
[42] or STRING [43] have been extensively used to identify 
new proteins associated to a phenotype [44-45]. They 
enable the creation of large PPI networks that can help to 
gain insight into disease and phenotype mechanisms. 
 
2.4 Tissue/Organ specificity 
High-throughput sequence methods have made it possible 
to explore gene expression patterns genome-widely, 
thereby offering the opportunity to describe the expression 
of gene within specific human organs and tissues. Such data 
can facilitate a better comprehension of the differences in 
the expression at the specific point where a disease takes 
place. Organ-specific patterns of gene expression may be of 
importance due to the promiscuity of genes, as they are 
expressed in many different tissues in the organism and at 
different levels.  For example, Ponten F, et al. demonstrated 
a different protein expression profile specific to tissue based 
on an analysis of over 2 million immunohistochemistry 
images annotated by pathologists [46]. This study 
demonstrated as well that proteins expressed in a well-
defined set of cell types are rather important for the 
function of those cells [47].  
Databases such as HOMER (Human Organ-specific 
Molecular Electronic Repository) [48], HPA (Human Protein 
Atlas) [49], GNF tissue atlas [50] or Pagenbase [51] aim to 
cover gene expression information in an organ-specific 
manner. The information contained is filtered from organ-
specific gene/proteins and disease as a result of the cross-
linking of several available data sources.  
 
2.5 Phenotypic outcomes 
When trying to understand the pathological phenotype it is 
also necessary to make the connection drug-disease and 
drug-target-disease. Hence databases connecting pathways, 
targets and molecules to unhealthy phenotypes are 
necessary. These phenotypes may be disease or 
toxicological side effects produced by the effect of a small 
molecule perturbation. There are many online sources that 
contain clinical information and allow the collection of data 
from clinicians, patients and pharmaceutical companies. 
Among others, a public computer-readable side effect 
resource (SIDER) that connects 888 drugs to 1,450 side 
effect terms was developed [52]. The Comparative 
Toxicogenomics Database (CTD) [53] is another example of 
a derived resource that includes curated information and 
data analysis tools about gene-chemical and chemical-
disease associations that promote the understanding of the 
effects of chemicals on human health. AERSs (created by the 
US FDA, World Health Organization, and Health Canada 
[54]), EudraVigilance (a system designed for collecting 
reports of suspected side effects created by the European 
medicines agency [55]), and JAPIC (which manages all 
package insert information of pharmaceutical products in 
Japan, under the approval of Health and Welfare Minister of 
Japan [56]) are other valuable data sources. However, there 
is no common terminology for therapeutic effects and side 
effects in each organization. Thus, to facilitate the coding of 
“regulatory data” in biopharmaceutical development and 
clinical trials, and the reporting of therapeutic and side 
effects, several dictionaries (terminologies) have been 
developed. The most widely used are MeSH (Medical 
Subject Headings [57]), MedDRA (Medical Dictionary for 
Regulatory Activities [58]), ICD-10 (International 
classification of diseases [59]), SNOMED CT (Systematized 
Nomenclature of Medicine- Clinical Terms [60]), the ATC 
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Classification System (Anatomical Therapeutic Chemical 
Classification System [61]), UMLS (Unified Medical Language 
System [62]), and J-ART (Japanese Adverse Reaction 
Terminology). 
 
 
3. Systems pharmacology 
3.1 From Target to Protein-Protein Interactions and 
Pathways Using Network Biology Approaches 
A disease can not only be a consequence of a genetic 
variation but might be also be a consequence of 
perturbations of complex intracellular and extracellular 
networks linking tissue and organ systems [16]. In fact, 
multiple changes in the same or different protein complexes 
and pathways can contribute to a disease. So the perception 
that human diseases are associated with a few dominant 
factors (reductionist view) is now replaced by a view of 
diseases as the outcome of many weak contributors (holistic 
view). 
The systems pharmacology method emerged as an all-
inclusive approach that analyzes events from all the 
interactions point of view, helping to understand the 
interaction mechanism between drugs and complex 
diseases (Figure 1) [63]. In systems pharmacology, the data 
are centered into network-based associations with an entity 
(drug, protein, gene, cell, phenotype, ...) defined by a node 
and the connection (interaction, association, deregulation, 
...) between two entities representing by an edge. These 
edges can be weighted and of different types to specify the 
degree and the direction of the connection. For example, 
drugs-target proteins can be compiled in a network based 
on protein-protein interactions data. Nodes define drugs 
and proteins, and edges define drug-protein and protein-
protein interactions. Then, including protein expression in 
cells and/or tissues, or phenotypes associated for each 
protein can complicate such network, but add to their 
usefulness. Similarly, differentiation of genes by a set of 
drugs can be embedded within a network. Such data can 
then be enriched with pathway information and connected 
to some physiological dysfunction observed for these drugs, 
allowing identifying the drug's action. Each physiological 
process is known to be regulated by signaling networks of 
chemicals and biomolecules. These reactions have different 
kinetics and time points, and complex networks control 
each phenotype or physiological function. For example, it is 
known that a drug is characterized by an Adverse Drugs 
Reaction (ADR) profile, which can be described as a toxicity 
network. This network may consist of one or more sites of 
actions that may also be dependent or independent of one 
another. Looking for example to hepatotoxicity, there is 
large panel of physiological features that can be generated 
by a particular drug and lead to drug-induced liver injury 
(DILI). Among them we notice, hepatitis, cholestasis, 
steatosis, hepatic granuloma or hepatic necrosis. 
Interestingly, although causing the same ADR, the drugs will 
not necessary interact with the same set of proteins which 
will not perturb the same pathways and consequently might 
lead to different physiological effects associated to DILI. 
With systems pharmacology, it is possible to represent the 
drug-target-pathway-physiological interactions in a network 
and to analyze the potential link and overlap between all 
the molecular events leading to DILI. By extension of this 
concept, a systematic association between drug, targets, 
clinical outcomes and side effects can be integrated in a 
network leading to the identification of novel drug actions 
[64]. 
The release of large set of gene expression data contributes 
also in Systems pharmacology. Based on the differential 
expression of more than 1,300 drugs to four human cell 
lines, the Connectivity Map (CMap) project produced gene 
expression signatures allowing for comparison of small 
molecules sharing similar physiological processes and 
diseases [65]. Calvert et al. used systems 
pharmacology/toxicology to prove the capabilities of this 
approach in drug repositioning. They used CMap to identify 
drugs with overlapping gene expression profiles with caloric 
restriction (CR), shown to induce retard aging in several 
animal models. Based on their longevity network analysis, 
they suggested eleven different compounds of which five 
were tested in C. elegans and four produced a lifespan 
effect [66]. Segura-Cabrera et al. developed a network 
framework that combines biomolecular interactions and 
known drug-target interactions for the prioritization of 
drugs, genes and pathways according to the biological 
context. Thereby demonstrating that various gene 
expression data or drug-target screening can prioritize drugs 
and pathways, respectively [67]. Finally, Chen et al. assessed 
if structurally similar compounds have similar cellular 
responses using the chemical structures and gene 
expression profiles of 11,000 compounds from LINCS. They 
concluded that two compounds tend to share similar gene 
expression profiles in cell lines for ~20% of the data [68]. 
 
3.2 Biological enrichment- diseases- toxicities classification 
limitation 
The more the data is integrated in biological network, the 
more complex is the analysis. To overcome this challenge, 
unsupervised and supervised graph theory approaches have 
been developed. Subnetworks  (hubs) on highly connected 
nodes can be identified using for example MCODE [69] or 
GIANT [70] with the help of Cytoscape. Biological 
enrichment is another possibility to organize the entities. 
Typically, when a set of genes is identified as interesting in 
relation to a disease, these genes are analyzed in the 
context of their PPI networks. Further analysis is usually 
carried out to enrich these networks with known pathways 
and disease-associations. There are quite a lot of biological 
human pathway resources, but most of them do not contain 
disease, drug or tissue specific information. Therefore 
computer programming, data curation and biostatistics are 
necessary for this data enrichment and data 
Short Running Title of the Article Journal Name, 2014, Vol. 0, No. 0    5 
characterization to lead to impact. Zhang et al. developed 
IPAD (Integrated Pathway Analysis Database), a resource for 
systematic enrichment analysis, by analyzing, identifying 
and validating drug, pathway, organ, disease and their 
associations [9]. More recently Handen et al. developed a 
tool called Lens for Enrichment and Network Studies of 
human proteins (LENS that executes systematic network, 
pathway and disease enrichment analysis on genes of 
interest [71].  
With the integration of tissue information, biological 
enrichment studies have been reported. For example, a 
combination of gene expression in human protein 
complexes revealed tissue specificity and pathology [72]. 
Similarly, McCall et al. [73] leveraged data from the GEO 
and ArrayExpress public repositories to build statistical 
models for the most annotated genes for 131 human and 89 
mouse tissue types to address which genes are expressed in 
a given cell type. Petrovskiy et al. presented an approach to 
assess tissue-specific gene knockout effects through target-
centric gene network. The model connects the expression of 
the group of target genes with their expression with 
machine learning models trained on expression data [74]. 
Such information is useful in understanding the chemical 
mechanism of action linked to the drug tolerance, drug 
efficacy, side effects, and risk assessment. 
Systems pharmacology studies have also been reported 
including Genome Wide Association Studies (GWAS). Sun et 
al. [75] compared network properties of the genes causing a 
disease and drug targets for five major disease categories 
(cancer, cardiovascular diseases, metabolic diseases, 
immune system disease, and nervous system disease). They 
collected the disease genes from genome wide association 
studies (GWAS) and their corresponding drugs based on 
drugs’ Anatomical Therapeutic Chemical (ATC) classification. 
With a network approach they found that disease genes 
were significantly enriched in targets, especially for cancers. 
In another study a human disease network involving 
disease-disease links among 108 diseases was built based 
on mRNA expression data and differential co-expression 
analysis. This enriched network shared known disease genes 
and drugs more significantly than those based on different 
expression analysis. Some new disease relationships were 
discovered, for instance obesity and psoriasis, which have 
recently been found to share similar molecular mechanisms. 
Additionally, it was also found that both the type of disease 
and the tissue affected influenced the degree of disease 
similarity. This led to  a global perspective of the human 
diseasome from the viewpoint of regulation mechanisms 
[76]. Finally, Zickenrott et al. introduced a novel network-
based approach for predicting target genes and other 
bioactive compounds that could revert disease phenotypes, 
throughout the reconstruction of gene regulatory networks 
(GNRs) corresponding to both disease and healthy 
phenotypes [77]. To validate it they predicted drug 
candidates for Rheumatoid arthritis. The enriched genes in 
the core of the disease network were targeted by copper 
sulfate and cyclosporine. Theses results confirmed a 
previous study [78]. 
 
3.3 Future research in the field of Systems pharmacology 
3.3.1) Dose-response 
In the context of a drug it is relevant not only to investigate 
the action of the drug at the target site, but also understand 
how the drug reached the target and the effective 
concentration. Taking a mechanistic view of the involved 
processes, pharmacokinetics/ pharmacodynamics (PK/PD) 
models might be useful to model the signaling network. It is 
important to study the dose together with time-response 
and gene expression, as it may explain why some diseases, 
such as cancer may respond to a treatment until at a certain 
point the treatment fails. Robinson et al. using a systems-
based toxicogenomics approach assessed quantitatively 
dose- and time- dependent effects on gene expression, in 
enriched GO biological processes perturbed by MeHg in 
mouse embryos during cranial neural tube closure. Altered 
expression was observed for 883 genes, including several 
previously characterized as crucial for the neural tube 
development. These genes were associated with specific GO 
biological processes that may underlie MeHg-induced 
teratogenic and neurodevelopmental toxicity outcome [79]. 
With the recent development of experimental tools that 
can generate sufficiently quantitative and thorough data, 
mathematical models such as exposure models, 
physiologically-based pharmacokinetic (PBPK) and 
biologically-based dose response (BBDR) can be used to 
approximate ADME (absorption, distribution, metabolism 
and excretion) processes, thus understanding the dose-time 
response effects of a drug in a more effective manner [80]. 
For example, Kirouac et al. developed a mathematical 
model incorporating cellular networks into PK-PD models to 
capture systems-level architectural features of oncogenic 
signaling networks [81]. 
 
3.3.2 Patient response variability 
With the concept that everyone responds to drug 
differently due to genetic predisposition, pharmacogenetics 
and pharmacogenomics began to be carried out. The 
objective is to explain why an individual responses 
differently to a drug therapy from being beneficial to an 
almost complete lack of therapeutic efficacy [82-83]. As 
knowledge of human genomics and therapeutics grows, it 
has become clear that drug response phenotypes are 
complex pathways, involving genes in pharmacokinetics and 
pharmacodynamics pathways and targets in downstream 
signaling parts of the pathways. Schizophrenia is an 
interesting example. One-third of the patients fail to 
respond favorably to a drug treatment. In addition, adverse 
drug reactions and side effects are often associated to the 
antipsychotics treatment leading to a lack of tolerability. 
Based on GWAS studies, a large panel of genetic 
associations and variations implicated in this pathology has 
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been suggested. In combination to pathway and protein-
protein interactions, patterns of genes belonging to the 
same biological pathways or on genes that show evidence 
of coregulation through gene expression analysis can be 
selected [84]. Two of them, Catechol-o-methyl transferase 
(COMT) and serotonin receptor 5-HT1A are drug-target 
considered for the treatment. However, it has been shown 
that the specific polymorphism of these two proteins had a 
negative impact on patient treated with clozapine, the gold 
standard drug treatment for schizophrenia [85]. Not only,  
multiscale network modeling approaches can be used to 
understand the etiology of a disease but they can also  
suggest the risk of non-efficacy due to drug target 
polymorphism.  
 
4. CONCLUSION 
With the emergence of big data and the advances in 
pharmacology that have taken place in the past years, there 
is a pressure to maximize drug efficacy, reduce toxicity and 
select responsive patients. Massive amount of data are 
generated and accumulated by new experimental 
technologies such as transcriptomics and genetics.  
Furthermore, centralized systems that facilitate the 
integration and standardization of diverse federated 
resources are in development. So, drug action can be 
explored across multiple scale of complexity, from 
molecular and cellular to tissue and organism levels over 
time and dose. With the development of new mathematical 
models and network-based strategies, systems 
pharmacology allows the assessment of the chemical effect 
at the biological systems (i.e., systems pharmacology and 
systems toxicology) more comprehensively. 
At the population level, understanding the individual 
differences in drug response in the context of biological 
networks is the new challenge in pharmacogenomics and 
personalized medicine. To do so, methods that integrate 
drug-target, clinical-outcome, and genetic factors using 
network biology have started to be reported [86-88]. Such 
analysis would definitively contribute to a better 
understanding of the variability in drug response and a 
more personalized approach to therapy. 
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FIGURES 
Figure 1: Representation of the in silico systems pharmacology strategy 
 
TABLES 
Table 1: Systems pharmacology data sources 
Resrouce Type Name URL Description 
Chemical-Protein 
Databases 
PubChem https://pubchem.ncbi.nlm.nih.gov Information of the interaction between 
chemicals and their targets  ChEMBL https://www.ebi.ac.uk/chembl 
ChemProt http://potentia.cbs.dtu.dk/ChemProt 
DrugBank http://www.drugbank.ca 
OpenPHACTS https://www.openphacts.org 
Toxcast & Tox21 https://ncats.nih.gov/tox21 
Chemogenomic 
and 
Toxicogenomic 
databases 
TG-GATEs http://toxico.nibiohn.go.jp Databases storing the gene expression 
profiles from in vivo  and  in vitro 
exposure to different compounds, at 
different concentrations, times or both 
ToxBank http://toxbank.net 
DrugMatrix https://ntp.niehs.nih.gov/drugmatrix 
ArrayExpress https://www.ebi.ac.uk/arrayexpress 
GEO http://www.ncbi.nlm.nih.gov/geo 
Expression Atlas https://www.ebi.ac.uk/gxa/home 
diXa http://www.dixa-fp7.eu 
LINCS https://lincs.ed.gov 
PPIs and Drug-
pathways 
databases 
KEGG http://www.genome.jp/kegg These databases have been developed 
to contain the wired gene-gene and 
protein-protein interaction information 
in the form of interaction pathways 
 
Reactome http://www.reactome.org 
Wikipathways http://www.wikipathways.org 
PID https://wiki.nci.nih.gov 
HPRD http://www.hprd.org 
Intact http://www.ebi.ac.uk/intact 
STRING http://string-db.org 
Tissue/Organ 
expression 
specificity 
databases 
HOMER http://discovery.informatics.iupui.edu/HOMER Tissue/organ specific gene expression 
profiles are stored in theses databases  HPA http://www.proteinatlas.org 
GNF tissues atlas https://cgwb.nci.nih.gov/cgi-bin/ 
Pagenbase http://bioinf.xmu.edu.cn/PaGenBase 
Phenotypic 
outcomes 
databases 
SIDER http://sideeffects.embl.de Databases connecting pathways, targets 
and molecules to unhealthy 
phenotypes, such as disease or 
toxicological side effects 
 
CTD http://ctdbase.org 
AERSs https://open.fda.gov/data/faers 
EudraVigilance https://eudravigilance.ema.europa.eu 
JAPIC http://database.japic.or.jp 
Terminology 
dictionaries 
MeSH https://www.nlm.nih.gov/mesh/ Therapeutic and side effect 
terminologies dictionaries MedDRA http://www.meddra.org 
ICD-10 http://www.who.int/classifications/icd/ 
SNOMED CT http://www.ihtsdo.org/snomed-ct 
ATC http://www.who.int/classifications/atcddd/ 
UMLS https://www.nlm.nih.gov/research/umls/ 
J-ART  
Network analysis 
and enrichment 
tools 
CMap http://www.broadinstitute.org/cmap/ Collection of GWAS data and pattern-
matching algorithms that enable the 
discovery of functional connection 
between drugs, genes and diseases 
Cytoscape http://www.cytoscape.org Software for the visualization of 
complex interaction networks 
IPAD http://bioinfo.hsc.unt.edu/ipad/ Resource for systematic enrichment 
analysis (associations between drug, 
pathway, organ and disease) 
LENS http://severus.dbmi.pitt.edu/LENS/ Software for the systematic network, 
pathway and disease enrichment 
analysis on genes of interest 
 
